Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
| ERICKSON AIR | EAC | 5.10% |
| ASSURED GUAR | AGO | 4.98% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Accenture Plc. (ACN - Snapshot Report) recently won a three-year deal from Italian Medicines Agency (AIFA) for the development, building and maintenance of an integrated Medicine Evaluation System.
According to the contract, AIFA will be using Accenture’s consulting and IT services, which is going to support AIFA’s administration and medical technology processes.
Accenture’s implementation of certain technical solutions will also help in strengthening AIFA’s relationship with end users.
Separately, Accenture is helping the insurance company AXA in streamlining the financial processes in AXA’s European operations.
This is basically under a multiyear deal, which was initiated in 2009. According to the deal, Accenture is helping AXA develop a SAP-based technology platform. This will primarily take care of the centralized finance and accounting (F&A) processes, which includes payables management, accounts receivable, month-end close and balance sheet reconciliations. The regions covered under this program include France, Italy, Ireland, Portugal, Spain and the U.K.
This should have a positive impact on Accenture in the near to mid term and also generate new business opportunities for the company. Other technology companies, such as Hewlett Packard Company (HPQ - Analyst Report) and Dell Inc. (DELL - Analyst Report) have also realized the increasing potential of the consulting segment and are coming out with their own solutions to tap the opportunity.
This apart, Accenture is also witnessing incremental growth from technological changes such as SaaS/cloud, mobility, analytics and digitization. Particularly, SaaS and cloud computing are other areas for the company’s growth.
Accenture’s comprehensive service offerings have made it a key IT service provider. A large product and service base has also led the company to the top spot in the market. Moreover, government orders continue to flow for the company.
We are encouraged by the steady flow of new businesses and believe that the trend will continue. However, increasing competition from IBM Corp. (IBM - Analyst Report) and a cautious spending environment may temper its growth prospects.
The company has a Zacks #2 Rank, implying a short-term Buy rating.
Get the full Snapshot Report on ACN - FREE
Get the full Analyst Report on HPQ - FREE
Get the full Analyst Report on IBM - FREE
Get the full Analyst Report on DELL - FREE